Next 10 |
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcomin...
2024-04-04 17:29:32 ET Gainers: Candel Therapeutics ( CADL ) +38% . Grindrod Shipping ( GRIN ) +28% . AngioDynamics ( ANGO ) +14% . Petco Health and Wellness Company ( WOOF ) +7% . Marinus Pharmaceuticals ( MRNS ) +5% . ...
2024-03-26 19:21:09 ET BioAtla, Inc. (BCAB) Q4 2023 Earnings Conference Call March 26, 2024, 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors Jay Short - Chairman, Chief Executive Officer and Co-Founder Richard Waldron - Chief F...
2024-03-26 16:42:37 ET Gainers: nCino ( NCNO ) +14% . Biomea Fusion ( BMEA ) +7% . Poseida Therapeutics ( PSTX ) +5% . Office Properties Income ( OPI ) +5% . Canopy Growth Corporation ( CGC ) +4% . Losers: Bow...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference c...
Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technology Differentiated preclinical activity for CAB anti-Nectin4-antibody drug conjugate (ADC) with superior efficacy to enfortumab vedotin analogue in a patient d...
2024-01-25 16:59:42 ET Gainers: Ocular Therapeutix, ( OCUL ) +5% . AppFolio ( APPF ) +4% . Sagimet Biosciences ( SGMT ) +3% . Xcel Energy ( XEL ) +3% . Digital World Acquisition ( DWAC ) +2% . Losers...
2023-12-21 11:18:41 ET More on BioAtla BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on BioAtla For further details see: BioAtla CEO purchases 50K common shares
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management ...
News, Short Squeeze, Breakout and More Instantly...
BioAtla Inc. Company Name:
BCAB Stock Symbol:
NASDAQ Market:
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the developm...
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcomin...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...